Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of surlorian in adults with autosomal dominant RYR1-related myopathy
2025-522343-18-00Phase 2Authorised
- Sponsor
- RyCarma Therapeutics
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in ryanodine receptor 1 related myopathy (RYR1-RD) comparing Surlorian with Placebo (2 arms). Primary endpoint: Change from Day 1 in 1-MSST after approximately 28 days. Planned start Jun 2026; status: authorised.
02
Drugs
Surlorian
03
Conditions
ryanodine receptor 1 related myopathy (RYR1-RD)
Beyond the preview
Go deeper on 2025-522343-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522343-18-00.